Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting
View Full Paper
Ask AI
Bookmark
Share
Key Points
The aim is to explore physician perspectives on the use of pembrolizumab for patients with high-risk early-stage triple-negative breast cancer in clinical settings.
Conducted a survey and focus group with eight physicians from the US Oncology Network
Included analysis of survey responses and thematic analysis of focus group discussions
Participants comprised six medical oncologists and two breast surgeons.
Pembrolizumab is widely adopted as the standard treatment for high-risk, early-stage triple-negative breast cancer.
Nonuse occurs rarely, generally due to contraindications or lack of medical oncology input after surgery referrals.
Management strategies for estrogen receptor-low/HER2-negative breast cancer mirror those of triple-negative breast cancer.
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Qualitative exploration reveals influential factors in treatment decision-making for triple-negative breast cancer patients.